Background Methotrexate (MTX) is used to treat psoriasis, a chronic inflammatory skin disease. Objectives To investigate the molecular mechanism of MTX in the treatment of psoriasis. Methods Regulatory T cells (Tregs) and effector T (Teff) cells were isolated from the blood of patients with psoriasis and healthy controls. The proliferation of Teff cells was detected by carboxyfluorescein succinimidyl ester assay. The interferon (IFN)-c and interleukin (IL)-17 levels were analysed by enzyme-linked immunosorbent assay. The expression of CD73 and FoxP3 were determined by flow cytometry. The expression of proteins in the AMPK/mTOR pathway were detected by Western blot analysis. Results The data suggested that patients with psoriasis have Tregs with decreased immune suppression function and reduced expression of CD73 compared with healthy controls. Moreover, MTX could significantly restore the immunosuppressive function of IL-17-secreting Tregs. This, in turn, inhibits aberrant proliferation of Teff cells in patients with psoriasis, reverses downregulation of CD73, upregulates phosphorylated AMPK and inhibits phosphorylated mTOR, and downregulates IL-17 and IFN-c levels. Conclusions We speculate that MTX can restore the immunosuppressive function of Tregs through upregulating CD73, activating AMPK and inactivating the mTOR pathway. These findings may partly explain the mechanism by which MTX treats psoriasis.
Summary
Background Methotrexate (MTX) is used to treat psoriasis, a chronic inflammatory skin disease. Objectives To investigate the molecular mechanism of MTX in the treatment of psoriasis. Methods Regulatory T cells (Tregs) and effector T (Teff) cells were isolated from the blood of patients with psoriasis and healthy controls. The proliferation of Teff cells was detected by carboxyfluorescein succinimidyl ester assay. The interferon (IFN)-c and interleukin (IL)-17 levels were analysed by enzyme-linked immunosorbent assay. The expression of CD73 and FoxP3 were determined by flow cytometry. The expression of proteins in the AMPK/mTOR pathway were detected by Western blot analysis. Results The data suggested that patients with psoriasis have Tregs with decreased immune suppression function and reduced expression of CD73 compared with healthy controls. Moreover, MTX could significantly restore the immunosuppressive function of IL-17-secreting Tregs. This, in turn, inhibits aberrant proliferation of Teff cells in patients with psoriasis, reverses downregulation of CD73, upregulates phosphorylated AMPK and inhibits phosphorylated mTOR, and downregulates IL-17 and IFN-c levels. Conclusions We speculate that MTX can restore the immunosuppressive function of Tregs through upregulating CD73, activating AMPK and inactivating the mTOR pathway. These findings may partly explain the mechanism by which MTX treats psoriasis.
What's already known about this topic?
• CD73 + regulatory T cells (Tregs) were markedly reduced in patients with psoriasis vulgaris compared with healthy controls.
• Methotrexate (MTX) is widely used to treat psoriasis and has also been reported to upregulate the expression of CD73 in melanoma.
What does this study add?
• We investigated the effect and mechanism of MTX on Treg function and its relationship to the CD73/AMPK/mTOR pathway in psoriasis therapy.
What is the translational message?
• These findings may partly explain the mechanism by which MTX treats psoriasis.
Psoriasis is one of the most common chronic, relapsing, immune-mediated inflammatory skin diseases. [1] [2] [3] The main clinical symptom of psoriasis is the presence of sharply distinguished chronic erythematous plaques covered by silvery white scales, which can be seen on body regions including the elbows, scalp, umbilicus and lumbar area. 4 The severity of psoriasis is characterized by hyperplasia of the epidermis, dilation and growth of blood vessels and infiltration of leucocytes into the dermis and epidermis. 5 The pathogenesis of psoriasis is not fully understood. Other than hereditary predisposition 6, 7 and environmental factors, 8, 9 abnormal immune response is regarded as the main cause of psoriasis and is closely involved in the pathogenesis of the disease.
10,11
Autoimmune disease is a clinical condition in which immune responses are abnormally activated and negative regulation of the immune system is repressed. 12, 13 It has been recently reported that abnormalities in both the number and function of CD4 + CD25 + regulatory T cells (Tregs) can reduce regulatory restraint and result in the hyperproliferation of psoriatic pathogenic T cells.
14,15
The adenosinergic pathway (CD39 and CD73) has been widely reported to play a crucial role in the way in which Tregs exert an immunosuppression function. 16 CD39 can remove extracellular ATP by hydrolysing ATP/UTP and ADP/ UDP into AMP. 16, 17 Extracellular AMP is then rapidly degraded into adenosine in the presence of CD73, and adenosine binds to the A2AR receptor at Tregs, ultimately triggering the accumulation of intracellular cAMP and therefore achieving local repression of the immune responses. 16 The reduced ATP/AMP ratio activates the AMPK signal pathway and the downstream signal pathways including mTOR signalling. 18 Previous data suggested that the expression of CD73 + Tregs was markedly reduced in patients with psoriasis vulgaris when compared with healthy individuals. 19 The immunosuppressive agent methotrexate (MTX) has been widely used to treat psoriasis. 20, 21 Moreover, it has been reported that MTX could upregulate the expression of CD73 in melanoma. 22 Therefore, in this study, we investigated the effect and mechanism of MTX on Treg function and its relationship to the CD73/ AMPK/mTOR pathway in psoriasis therapy.
Materials and methods

Clinical samples
Blood samples were obtained from 30 patients with psoriasis and 30 sex-matched healthy donors. Informed consent was obtained from each patient before blood was taken and records of oral informed consent were kept on file. Patient characteristics are provided in Table 1 . The recruitment criteria were as follows: participants had not received any systematic treatment for at least 4 weeks prior to entering this study; conditions such as significant infection and immune suppression were excluded and participants with significant renal, hepatic or other diseases were also excluded. 5, 23 This study was approved by Huashan Hospital and the experiments were approved by the ethical committee of Huashan Hospital, which is affiliated with Fudan University. 
Cell isolation
RNA interference assay
AMPK small interfering (si)RNA and negative control were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). The cells were plated at 50% confluence, transfected with 50 nmol À1 siRNA overnight in Opti-MEM containing Tregs isolated from patients with psoriasis and healthy controls were subjected to flow cytometry assay to determine the expressions of CD73 and FoxP3. (d) Lysates of Tregs from patients with psoriasis and healthy controls were prepared and analysed using Western blot analysis for the indicated proteins. P < 0Á05 was considered to represent statistical significance. *P < 0Á05, **P < 0Á01, ***P < 0Á001 vs. the normal group.
(a) (c)
were detected by flow cytometry and the expression was calculated using FlowJo software (FlowJo LLC, Ashland, OR, U.S.A.).
Enzyme-linked immunosorbent assay
To detect the supernatant levels of interferon (IFN) 
Statistical analysis
All in vitro experiments were repeated at least three times. Parametric data in different groups were examined for the homogeneity of variance, and the data with equal variances were compared using one-way ANOVA followed by least significant difference method for the intergroup comparisons; nonparametric data or data with unequal variances were compared using Kruskal-Wallis rank test followed by the Dunnett T3 method for intergroup comparisons (GraphPad Software, San Diego, CA, U.S.A.). P < 0Á05 was considered to be statistically significant.
Results
The proliferation of effector T cells and secretion of interleukin-17 and interferon-c were more active in patients with psoriasis
Although aberrant activation of immune responses has been observed in patients with psoriasis, the exact mechanism of action remains unclear. 24, 25 We first used CSFE assay to analyse the proliferation of Teff cells. As shown in Figure 1 (a), compared with healthy controls, samples obtained from patients with psoriasis had more M3 generation Teff cells and fewer M1 generation Teff cells (Fig. 1a) . These results suggest that the proliferation of Teff cells in patients with psoriasis was more rapid than in healthy controls. To evaluate the relationship between cytokines and the proliferation of Teff cells, we measured the serum levels of IL-17 and IFN-c both in patients with psoriasis and healthy controls. The data showed that both IL-17 and IFN-c were significantly upregulated during the pathogenesis of psoriasis (Fig. 1b) , implying that Teff cells in the tissue might be affected by the aberrant secretion of IL-17 and IFN-c.
The CD73/AMPK signal pathway in regulatory T cells was inactive in patients with psoriasis
Upon stimulation by inflammatory factors the normal Tregs have a tendency to undergo differentiation into IL-17-secreting Tregs, which have a decreased immune suppression function. 26, 27 Additionally, CD73, a crucial cell surface protein expressed in Tregs, has been shown to play a critical role in negatively modulating the immune responses of Teff cells. 28, 29 As depicted in Figure 1(c) , the expression level of CD73 on Tregs was markedly reduced in patients with psoriasis when compared with that of healthy controls. However, there was little change in FoxP3 expression between the two groups. The striking reduction in the number of CD73 + Tregs may affect the suppressive capacity of psoriatic Tregs, and thus contribute to aberrant Teff-cell proliferation in patients with psoriasis. The AMPK/mTOR signalling pathways were analysed by Western blot analysis. P < 0Á05 was considered to represent statistical significance. *P < 0Á05, **P < 0Á01, ***P < 0Á001 vs. the control group. Con, control.
CD73 has been reported to play an important role in the immune repression of normal Tregs by hydrolysing ATP to AMP. 16 As shown in Figure 1(d) , the phosphorylation of AMPK was greatly reduced in Tregs from patients with psoriasis.
Furthermore, mTOR, an important marker related to proliferation and immunity, which may be downstream of AMPK, was highly activated. All these results indicated that the CD73/AMPK signal pathway in Tregs is inactive in patients with psoriasis. The AMPK/mTOR signalling pathways were analysed by Western blot analysis. P < 0Á05 was considered to represent statistical significance. *P < 0Á05, **P < 0Á01, ***P < 0Á001 vs. the control group. Con, control. The AMPK/mTOR signalling pathways analysed by Western blot analysis. P < 0Á05 was considered to represent statistical significance. *P < 0Á05, **P < 0Á01, ***P < 0Á001 vs. the control group. Con, control.
Methotrexate treatment restored the inhibitory function of regulatory T cells, downregulated the interleukin-17 and interferon-c levels, and regulated AMPK/mTOR pathway in patients with psoriasis
In order to determine whether MTX restored the function of Tregs and induced proliferation inhibition of Teff cells in patients with psoriasis, Tregs from patients with psoriasis were first treated with MTX and subsequently cocultured with Teff cells. The results showed that MTX treatment induced a significant growth inhibition of Teff cells (Fig. 2a, upper) , decreasing the number of Teff cells in M3 generation (Fig. 2b,  bottom) , which suggested that MTX could restore the function of Tregs and restrain the proliferation of Teff cells in patients with psoriasis. Moreover, the results depicted in Figure 2(b) show that MTX treatment greatly reduced the level of IL-17 and IFN-c secreted from Tregs. In addition, we investigated the CD73 expression by flow cytometry in addition to phosphorylation of AMPK and mTOR by Western blot analysis in patients with psoriasis. The results suggest that MTX treatment activated CD73 and AMPK, and thus attenuated the phosphorylation level of mTOR in a dosedependent manner (Fig. 2c, d ). Through the activation of CD73 and AMPK and the inactivation of mTOR, MTX treatment restored the function of Tregs, inhibited the proliferation of Teff cells and downregulated the levels of IL-17 and IFN-c in patients with psoriasis.
CD73 inhibition or AMPK knockdown contributed to Teffector-cell proliferation and upregulation of ineterleukin-17/interferon-c in patients with psoriasis
To demonstrate further the roles of CD73 and AMPK in Tregs in the pathogenesis of psoriasis, we attempted to inhibit CD73 activity by using an antagonist APCP or by knocking down the expression of AMPK. (Fig. 3) .
mTOR participates in modulating T-effector-cell proliferation and the secretion of interleukin-17 and interferon-c in patients with psoriasis
To prove that mTOR was involved in facilitating the pathogenesis of psoriasis, we attempted to overexpress mTOR or inhibit the kinase activity of mTOR in Tregs by using the small-molecule compound rapamycin. MTX could significantly restore immune suppression function of Tregs to relieve aberrant proliferation of Teff cells in patients with psoriasis, and reverse the downregulation of CD73/AMPK/mTOR in addition to downregulating IL-17 and IFN-c levels. The data suggested that when overexpressing mTOR, MTX could upregulate the expression of CD73, and activate AMPK, but had no influence on the function of Tregs and the IL-17 and IFN-c levels. However, when cells were treated with rapamycin at a concentration of 100 lmol À1 , the activity of CD73
and AMPK had no change, but the function of Tregs was restored and the IL-17 and IFN-c levels were inhibited, which indicated that mTOR was in the downstream of CD73 and AMPK. MTX restored the inhibitory function of Tregs, including the hyperproliferation of inhibited Teff cells and secretion of IL-17 and IFN-c via upregulating CD73 and activating AMPK, and inhibiting the mTOR pathway (Fig. 4) .
Discussion
The pathogenesis of psoriasis is not fully understood and an abnormal immune response is regarded as the main cause. 10, 11 In this study, we found that Teff-cell proliferation was more rapid in patients in psoriasis than in healthy individuals, which is consistent with previous reports. 30 The levels of IL-17 and IFN-c were higher in the blood of patients with psoriasis, when compared with healthy individuals. Elevated IL-17 levels have been widely reported to be associated with psoriasis, as high IL-17 promotes hyperproliferation and differentiation of keratinocytes, which ultimately results in neutrophilic microabscess formation. 31 IFN-c has also been demonstrated to play an important role in facilitating inflammation in psoriasis. 32 Tregs were easily differentiated into IL-17-secreting Tregs with reduced expressions of CD73. 19, 33 Our study found that the secretion of IL-17 was elevated and the expression of CD73 was significantly downregulated. This further confirmed the attenuated function of Tregs in patients with psoriasis. In 2007, Deaglio et al. discovered that adenosine enzymes mediated the immune repression function of normal Tregs by reducing the ATP/AMP ratio, 16 and thus the AMPK signal pathway might be activated. 34 Consistent with these investigations, our results showed that AMPK phosphorylation was greatly reduced, and the mTOR levels were correspondingly elevated in patients with psoriasis. These results indicated that downregulation of CD73 attenuated immune repression of Tregs by inhibiting AMPK and activating mTOR signalling. Our results showed that MTX could significantly restore the immune suppression function of Tregs, prevent uncontrolled proliferation of Teff cells in patients with psoriasis, and downregulate IL-17 and IFN-c levels. Moreover, MTX can also increase CD73 levels, upregulate AMPK phosphorylation and inhibit mTOR phosphorylation (Fig. 2) .
We further investigated the relationship between MTX and the CD73/AMPK/mTOR pathway. In the presence of APCP, MTX showed no influence on the expression of CD73 and the function of Treg cells. Moreover, when knocking down AMPK by siRNA, MTX could increase CD73, but have little influence on AMPK, mTOR or the function of Tregs, which indicated that AMPK is downstream of CD73 (Fig. 3) . Furthermore, we confirmed the function of mTOR in the pathogenesis of psoriasis. When mTOR is overexpressed, MTX can upregulate the expression of CD73 and activate AMPK, but has no influence on the function of Tregs. However, when cells were treated with rapamycin, the activity of CD73 and AMPK did not change, but the function of Tregs were restored and the IL-17 and IFN-c levels were reduced, which indicated that mTOR was downstream of CD73 and AMPK (Fig. 4) .
In conclusion, we speculated that MTX could restore the immunosuppressive function of Tregs which inhibit the hyperproliferation of Teff cells and the secretion of IL-17 and IFN-c. MTX contributed to psoriasis therapy via upregulating CD73, activating AMPK, and inactivating the mTOR pathway (Fig. 5) . However, we have only confirmed the signal pathway in Tregs from patients with psoriasis, and we will establish the animal model to confirm the efficacy of MTX and the function of the CD73/AMPK/mTOR pathway in future studies. These studies might partly underline the mechanism of how MTX treats psoriasis, thus contributing to our understanding of psoriasis therapy.
